checkout IMCL which has a revenues of only $1.5 million but a MARKET CAP of $2.7 BILLION! CTE's market cap is only $12 million. so even though CTE has more revenues than IMCL, IMCL is trading at 225 times more than CTE?
like i said b4, CTE is way undervalued for a biotech and only 5 years ago IMCL was a penny stock too.
Either CTE's Market Cap has to increase or CTE will be easily bought out by other expensive biotechs. By the way IMCL is trading at 1,800 times sales which makes it impossible to imagine that CTE actually has more sales than IMCL but trades at so much lower Market Cap of only $9 million.
So what's the difference between the 2 companies? 1 is into cancer and the other into heart diseases. Both will have strong demand in the future yet IMCL has a Market Cap of $2.7 billion compared to CTE's $9 million.
That's why eventually CTE's Market Cap has to increase or they will be bought out by some many other overvalued biotechs out there.